<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5002">
  <stage>Registered</stage>
  <submitdate>21/05/2015</submitdate>
  <approvaldate>21/05/2015</approvaldate>
  <nctid>NCT02459938</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia</studytitle>
    <scientifictitle>A Randomized Open-label Crossover Study to Compare the Safety and Efficacy of ZP-Glucagon to Injectable Glucagon in the Treatment of Insulin-induced Hypoglycemia in Subjects With Type-1 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP-2014-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypoglycemia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Glucagon (ZP-Glucagon)
Treatment: drugs - Glucagon (GlucaGen)

Experimental: ZP-Glucagon 0.5 mg - glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes

Experimental: ZP-Glucagon 1.0 mg - glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes

Active Comparator: Glucagon by injection, 0.5 mg - glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg

Active Comparator: Glucagon by injection, 1.0 mg - glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg


Treatment: drugs: Glucagon (ZP-Glucagon)
chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes

Treatment: drugs: Glucagon (GlucaGen)
recombinant glucagon administered via subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of subjects achieving normoglycemia</outcome>
      <timepoint>30 minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time at which normoglycemia is first reached</outcome>
      <timepoint>3 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time at which maximal glucose levels are reached</outcome>
      <timepoint>3 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Increases in blood glucose by 15 minute intervals</outcome>
      <timepoint>3 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak Plasma Concentration (Cmax)</outcome>
      <timepoint>3 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration versus time curve (AUC)</outcome>
      <timepoint>3 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Women or men 18 to 60 years with type-1 diabetes on daily insulin treatment
             (basal-bolus injection regimen or insulin pump) for at least two years, on a total
             daily dose that has been stable for the last 3 months preceding enrollment (no more
             than 20% variation), and with a current level of glycated hemoglobin between 6.5% and
             10%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any history of hypoglycemic coma or hypoglycemic seizures.

          -  Any episode of severe hypoglycemia (requiring treatment) within one month prior to
             study start.

          -  Any history of pheochromocytoma or insulinoma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>3005 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Zosano Pharma Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether glucagon administered by microneedle patch
      is comparable to glucagon administered by injection pen in the treatment of insulin-induced
      hypoglycemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02459938</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Neale Cohen, MD</name>
      <address>Baker ID Heart and Diabetes Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>